What are the best treatments for Duchenne muscular dystrophy?

Current treatment for Duchenne muscular dystrophy focuses on a multidisciplinary approach that combines chronic corticosteroid therapy to preserve muscle strength with proactive management of cardiac and respiratory complications. While there is no cure, personalized care plans involving physical therapy, orthopedic intervention, and emerging gene-targeted therapies are significantly extending both the quality and length of life for those living with Duchenne muscular dystrophy.

What are the primary pharmacological treatments for Duchenne muscular dystrophy?

The cornerstone of pharmacological management for Duchenne muscular dystrophy is the long-term use of corticosteroids, specifically prednisone or deflazacort (Emflaza). These medications help stabilize muscle membranes and slow the progression of muscle weakness. In recent years, the FDA has approved several exon-skipping therapies—such as eteplirsen (Exondys 51), golodirsen (Vyondys 53), and viltolarsen (Viltepso)—which are designed for patients with specific genetic mutations. These treatments aim to increase the production of truncated but functional dystrophin protein. Because treatment effectiveness for Duchenne muscular dystrophy varies significantly based on an individual's specific genetic mutation, these therapies must be prescribed and monitored by a specialized neuromuscular team.

What non-pharmacological interventions are recommended?

Management of Duchenne muscular dystrophy requires a comprehensive approach to maintain physical function and prevent secondary complications. Physical and occupational therapy are essential to prevent joint contractures and maintain mobility for as long as possible. As the disease progresses, non-invasive ventilation (NIV) and cardiac medications, such as ACE inhibitors or beta-blockers, are frequently introduced to manage the cardiomyopathy and respiratory decline common in this condition. The following list outlines the essential components of a proactive care plan:

• Corticosteroids: Daily or intermittent dosing to maintain muscle strength.


• Physical Therapy: Stretching and low-impact exercise to improve joint range of motion.


• Cardiac Monitoring: Annual echocardiograms and/or cardiac MRIs starting early in childhood.


• Respiratory Support: Baseline pulmonary function testing and eventual use of assisted cough devices.


• Orthopedic Care: Monitoring for scoliosis and potential surgical intervention to stabilize the spine.

Which specialists should be part of the care team?

Because Duchenne muscular dystrophy is a systemic condition, care should be coordinated through a multidisciplinary clinic. A typical team includes a pediatric neurologist or neuromuscular specialist, a cardiologist, a pulmonologist, a physical therapist, a clinical geneticist, and an orthopedic surgeon. This team works together to address the evolving needs of the patient, ensuring that interventions are timed correctly to maximize physical function.

What is the status of emerging therapies and clinical trials?

The landscape for Duchenne muscular dystrophy is rapidly evolving through clinical research. Gene therapy, which seeks to deliver a functional micro-dystrophin gene to muscle cells, is currently the subject of intense investigation and early-stage clinical trials. Other research areas include anti-fibrotic drugs and inhibitors of muscle cell degradation. Patients and families are encouraged to consult resources like ClinicalTrials.gov or the 38 members of the DiseaseMaps.org community to learn about ongoing research and access to potential trials.

Next steps

• Consult a board-certified neuromuscular specialist to discuss genetic testing and personalized treatment options.


• Schedule an initial evaluation with a multidisciplinary clinic specializing in muscular dystrophy.


• Connect with the Duchenne muscular dystrophy community on DiseaseMaps.org to share experiences and learn from others.


• Review current clinical trials via the NIH or patient advocacy foundations to understand eligibility for emerging therapies.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice; all treatment decisions must be made in consultation with your personal healthcare team.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Duchenne Muscular Dystrophy.


• Orphanet: Duchenne Muscular Dystrophy (ORPHA:576).


• Parent Project Muscular Dystrophy (PPMD): Care Guidelines for Duchenne.


• OMIM (Online Mendelian Inheritance in Man): Dystrophin; DMD (Entry #310200).